Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Travere Therapeutics, Inc.

SAN DIEGO, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Travere

image desc for 26

Therapeutics, Inc. (NASDAQ: TVTX) today announced that on October 10, 2022, the Compensation Committee of its Board of Directors granted inducement equity grants to seven new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 25,750 shares of its common stock. These inducement RSUs are subject to the terms of Travere’s 2018 Equity Incentive Plan (“2018 Plan”), but were granted outside of the 2018 Plan and were granted as inducements material to the new employees entering into employment with Travere in accordance with Nasdaq Listing Rule 5635(c)(4).

The RSUs vest over four years, with 25% of the shares vesting on each anniversary of the grant date, subject to the new employee’s continued service relationship with Travere through the applicable vesting dates.

About

image desc for 33

Travere Therapeutics

At

image desc for 34

Travere

image desc for 35

Therapeutics, we

image desc for 36

are in rare for life. We

image desc for 37

are

image desc for 38

a biopharmaceutical company that comes together

image desc for 39

every day to help patients, families and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent –

image desc for 40

that is why our global team works with the rare disease community to identify, develop and deliver

image desc for 41

life-changing therapies. In pursuit of this mission,

image desc for 42

we continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference

image desc for 43

in their lives and provide hope – today and tomorrow. For

image desc for 44

more information, visit travere.com

Contact:
Investor Relations
888-969-7879                                                 
IR@travere.com